Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Treatment with rifaximin for overt hepatic encephalopathy recurrence in patients on liver transplantation waitlist appears to significantly lessen hospital admissions associated with spontaneous bacterial peritonitis, ascites and variceal bleeding, a recent study has found. Furthermore, it helps reduce requirement for transplant prioritization and prolong time to hospital readmission.
Mood stabilizers for bipolar disorder are implicated in the risk of stroke, which appears to vary among the different types of drugs, as suggested in a recent study. Carbamazepine carries the highest risk of stroke, followed by valproic acid, whereas lithium and lamotrigine have a null effect.
Metaraminol may be a better vasopressor than ephedrine for mothers undergoing elective caesarean section, a recent meta-analysis has found.
Use of intravitreal antivascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular oedema (DME) in routine clinical practice does not escalate the hazard of cerebrovascular disease, myocardial infarction or major bleeding within 6 months after treatment, reports a study.
Administering ferric carboxymaltose infusion results in faster and more efficient normalization of haemoglobin and iron status parameters, with a better tolerability profile, when compared with oral ferrous sulphate in patients with anaemia secondary to acute gastrointestinal (GI) bleeding, as shown in a recent study.
The ProGlide vascular closure device (VCD) shows better safety profile than the Prostar XL VCD in terms of vascular complications and acute kidney injury (AKI) following transcatheter aortic valve replacement (TAVR), a post hoc analysis of the BRAVO-3* study finds.
The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.
Special Reports
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
At a Boehringer Ingelheim-sponsored symposium, held in conjunction with the joint 12th International Diabetes Federation Western PacificRegion Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in Kuala Lumpur, two prominent speakers discussed therapidly evolving treatment landscape for diabetes, focusing on the implications of heart failure (HF) and chronic kidney disease (CKD) in thediabetes continuum.
Dapagliflozin 5 mg and 10 mg FC tab
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Conference Reports
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
The combination of TAS-118 and oxaliplatin led to significantly greater survival compared with the S-1 and cisplatin combination in patients with metastatic or recurrent HER2-negative gastric cancer, the phase III SOLAR* study showed.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.
The survival benefit with ramucirumab was consistent in patients with advanced hepatocellular carcinoma (HCC) and high alpha-fetoprotein (AFP) levels regardless of whether they were previously treated with transarterial chemoembolization (TACE), a post hoc analysis of pooled data from the REACH/REACH-2 studies shows.
Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.
Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Multimedia
